Showing 901-910 of 974 results for "".
- Eyevensys Presents Initial Data from Phase 1/2 Trial of Non-Viral Gene Therapy for Ocular Diseaseshttps://modernod.com/news/eyevensys-presents-initial-data-from-phase-1-2-trial-of-non-viral-gene-therapy-for-ocular-diseases/2476987/Eyevensys this week presented results from part 1 of its phase 1/2 study for noninfectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the nov
- Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Franciscohttps://modernod.com/news/oxurion-nv-to-provide-business-and-clinical-update-at-aao-and-ois-meetings-in-san-francisco/2476969/Oxurion NV announces that the company will be providing a business and clinical update at the American Academy of Ophthalmology’s annual meeting (AAO) and Ophthalmology Innovation Summit (OIS@AAO) in San Francisco. Patrik De Haes, MD, CEO of Oxurion will be presenting the company’s b
- MicroSurgical Technology Releases MST 19-Gauge Ahmed Micro Stent Cutterhttps://modernod.com/news/microsurgical-technology-releases-mst-19-gauge-ahmed-micro-stent-cutter/2476768/To address challenging microstent revision surgery, MicroSurgical Technology (MST), in collaboration with glaucoma and cataract surgeon Ike Ahmed, MD, has developed the MST 19-gauge Ahmed Micro Stent Cutter. Bringing precision and control, the new instrument enables an efficient and minimally inv
- Eye Specialist Works to Prevent Motor Vehicle Related Traumatic Eye Injurieshttps://modernod.com/news/eye-specialist-works-to-prevent-motor-vehicle-related-traumatic-eye-injuries/2476751/Within a 6-week period, Grady Memorial Hospital eye specialist Yousuf Khalifa, MD, witnessed an unusual set of traumatic eye injuries. Three patients, all riding with their windows down, suffered serious eye injuries when the glass in their exterior rear-facing side
- Prism Vision Group Announces Launch of New Brandhttps://modernod.com/news/prism-vision-group-announces-launch-of-new-brand/2476726/Prism Vision Group, an ophthalmology administrative services care provider organization, was officially launched. The new entity is led by Steven Madreperla, MD, PhD, a practicing ophthalmologist and one of the founding partners of NJRetina, a specialty retina practice with roots that reac
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara
- Jefferson and Wills Eye Launch World’s First Center Focused on Connections Between the Eye and the Brainhttps://modernod.com/news/jefferson-and-wills-eye-launch-worlds-first-center-focused-on-connections-between-the-eye-and-the-brain/2476574/Thomas Jefferson University, in partnership with Wills Eye Hospital and thanks to the generosity of several prescient philanthropists, has launched the world’s first center focused on the visual signatures of neurological diseases. The William H. Annesley, Jr., MD ’48 EyeBrain Center will explore
- Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRShttps://modernod.com/news/eyenovia-announces-presentation-of-successful-phase-3-studies-at-the-ascrs/2476557/Eyenovia announced the safety and efficacy results from the company’s two phase 3 trials, MIST-1 and MIST-2, for pharmacologic mydriasis (pupil dilation). The results were presented by David Wirta, MD, from the podium during the joint ASCRS-ASOA annual meeting, on May 5, 2019 in S
- Results of Lumega-Z Data to be Presented at ARVOhttps://modernod.com/news/results-of-lumega-z-data-to-be-presented-at-arvo/2476474/Guardion Health Sciences Scientific Advisory Board member William Sponsel, MD, will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting in Vancouver, Canada, which will be held from April 28, 2019 to May 2, 2019. The abstract is titled
- Children’s Hospital Los Angeles Receives $1.6M Grant to Study Retinoblastomahttps://modernod.com/news/childrens-hospital-los-angeles-receives-1-6m-grant-to-study-retinoblastoma/2476397/Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age and accounts for approximately 4% of childhood cancers. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. David Cobrinik, MD, PhD, of The Saban Researc